ALNYvsAMGN
Alnylam Pharmaceuticals IncvsAmgen Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.
Alnylam Pharmaceuticals Inc
$313.79
-19.78%
Amgen Inc
$348.62
+6.70%
60-day price, rebased to 100
Round-by-round
Valuation upside
-30.50% vs -41.60% to DCF fair value
Balance-sheet strength
Altman Z 5.77 vs 1.78
Fundamental quality
Piotroski 6.00 vs 8.00 (of 9)
Growth + margins
Rule-of-40 77.70 vs 32.00
60-day momentum
-7.18% vs +1.97% price return
Market-cap liquidity
$41.4B vs $188.8B
Verdict
Across6categories,the two names are evenly matched —3wins each. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.
Backtest a strategy onALNYorAMGN
Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.